| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Advanced bronchoscopic techniques for the diagnosis and treatment of peripheral lung cancer
|
Kramer, Tess
|
|
|
161 |
C |
p. 152-162
|
artikel
|
| 2 |
ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis
|
Cirne, Filipe
|
|
|
161 |
C |
p. 9-17
|
artikel
|
| 3 |
Analysis of the baseline performance of five UK lung cancer screening programmes
|
Balata, Haval
|
|
|
161 |
C |
p. 136-140
|
artikel
|
| 4 |
A nationwide population-based cohort study of surgical care for patients with superior sulcus tumors: Results from the Dutch Lung Cancer Audit for Surgery (DLCA-S)
|
Winkelman, J.A.
|
|
|
161 |
C |
p. 42-48
|
artikel
|
| 5 |
A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncology research group 1632
|
Noro, Rintaro
|
|
|
161 |
C |
p. 49-54
|
artikel
|
| 6 |
A reply to “Importance of designing sample size, subgroup analysis, and covariate presentation: Towards a better randomized controlled trial”
|
Kużdżał, Jarosław
|
|
|
161 |
C |
p. 201
|
artikel
|
| 7 |
A risk classification system predicting the cancer-specific survival for postoperative stage IB non-small-cell lung cancer patients without lymphovascular and visceral pleural invasion
|
Tu, Zegui
|
|
|
161 |
C |
p. 114-121
|
artikel
|
| 8 |
Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer
|
Morimoto, Kenji
|
|
|
161 |
C |
p. 26-33
|
artikel
|
| 9 |
Clinical relevance of circulating activin A and follistatin in small cell lung cancer
|
Barany, Nandor
|
|
|
161 |
C |
p. 128-135
|
artikel
|
| 10 |
Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC – The ETOP/EORTC SPLENDOUR and AMGEN-249 trials
|
Peters, Solange
|
|
|
161 |
C |
p. 76-85
|
artikel
|
| 11 |
Contents
|
|
|
|
161 |
C |
p. iv-vi
|
artikel
|
| 12 |
Does large NGS panel analysed using exome tumour sequencing improve the management of advanced non-small-cell lung cancers?
|
Niogret, Julie
|
|
|
161 |
C |
p. 98-107
|
artikel
|
| 13 |
Editorial Board
|
|
|
|
161 |
C |
p. iii
|
artikel
|
| 14 |
Erratum to “Letter to the Editor: Comment on ‘Malignant pleural mesothelioma: Comparison of surgery-based trimodality therapy to medical therapy at two tertiary academic institutions’’’ [Lung Cancer 159 (2021) 127]
|
Maat, Alexander P.W.M.
|
|
|
161 |
C |
p. 202
|
artikel
|
| 15 |
Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC
|
Zhou, Nanruoyi
|
|
|
161 |
C |
p. 34-41
|
artikel
|
| 16 |
Importance of designing sample size, subgroup analysis, and covariate presentation: Towards a better randomized controlled trial
|
Hara, Akio
|
|
|
161 |
C |
p. 200
|
artikel
|
| 17 |
Infectious complications of EBUS-TBNA: A nested case-control study using 10-year registry data
|
Kang, Noeul
|
|
|
161 |
C |
p. 1-8
|
artikel
|
| 18 |
Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer
|
Huicochea Castellanos, Sandra
|
|
|
161 |
C |
p. 60-67
|
artikel
|
| 19 |
Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02–15 study)
|
Auliac, Jean-Bernard
|
|
|
161 |
C |
p. 122-127
|
artikel
|
| 20 |
NTRK fusions in lung cancer: From biology to therapy
|
Harada, Guilherme
|
|
|
161 |
C |
p. 108-113
|
artikel
|
| 21 |
Optimising fusion detection through sequential DNA and RNA molecular profiling of non-small cell lung cancer
|
Moore, David A.
|
|
|
161 |
C |
p. 55-59
|
artikel
|
| 22 |
Post-operative radiation therapy for non-small cell lung cancer: A comparison of radiation therapy techniques
|
Jairam, Vikram
|
|
|
161 |
C |
p. 171-179
|
artikel
|
| 23 |
Pre-surgical assessment of mediastinal lymph node metastases in patients having ≥ 30 mm non-small-cell lung cancers
|
Zhu, Yeqing
|
|
|
161 |
C |
p. 189-196
|
artikel
|
| 24 |
Prognostic relevance of pleural invasion for resected NSCLC patients undergoing adjuvant treatments: A propensity score-matched analysis of SEER database
|
De Giglio, Andrea
|
|
|
161 |
C |
p. 18-25
|
artikel
|
| 25 |
Prognostic value of CYFRA 21.1 in malignant mesothelioma: A brief report of the randomized phase II trial NVALT19
|
de Gooijer, Cornedine J.
|
|
|
161 |
C |
p. 197-199
|
artikel
|
| 26 |
Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma
|
Takamochi, Kazuya
|
|
|
161 |
C |
p. 163-170
|
artikel
|
| 27 |
Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON)
|
Saito, Go
|
|
|
161 |
C |
p. 86-93
|
artikel
|
| 28 |
The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer
|
Joosten, P.J.M.
|
|
|
161 |
C |
p. 141-151
|
artikel
|
| 29 |
Two cases of non-small cell lung cancer patients with somatic or germline EGFR R776H mutation
|
Guo, Tianxing
|
|
|
161 |
C |
p. 94-97
|
artikel
|
| 30 |
Use of tyrosine kinase inhibitors during pregnancy for oncogenic-driven advanced non-small cell lung carcinoma
|
Boudy, Anne-Sophie
|
|
|
161 |
C |
p. 68-75
|
artikel
|
| 31 |
Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study
|
Clarke, Jeffrey M.
|
|
|
161 |
C |
p. 180-188
|
artikel
|
Tijdschrift beschrijving